Darrah, Patricia A.
DiFazio, Robert M.
Maiello, Pauline http://orcid.org/0000-0002-5188-8420
Gideon, Hannah P.
Myers, Amy J.
Rodgers, Mark A. http://orcid.org/0000-0001-9800-3362
Hackney, Joshua A. http://orcid.org/0000-0003-1859-8808
Lindenstrom, Thomas
Evans, Thomas
Scanga, Charles A. http://orcid.org/0000-0003-3654-5603
Prikhodko, Victor
Andersen, Peter
Lin, Philana Ling
Laddy, Dominick
Roederer, Mario
Seder, Robert A. http://orcid.org/0000-0003-3133-0849
Flynn, JoAnne L. http://orcid.org/0000-0001-7874-8981
Funding for this research was provided by:
Bill and Melinda Gates Foundation
Aeras Global Tuberculosis Vaccine Foundation
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (T32 AI060525)
Article History
Received: 3 January 2019
Accepted: 3 May 2019
First Online: 28 May 2019
Competing interests
: The authors from University of Pittsburgh, NIH and Aeras have no competing interests. At Statens Serum Institut, Peter Andersen is a coinventor of patents relating to cationic liposomes as vaccine adjuvants and of patents relating to TB fusion protein Ag85B-ESAT-6-Rv2660 (H56). All rights have been assigned to Statens Serum Institut (SSI).